

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup>:</b> A61L 27/00, 29/00, 31/00	<b>A1</b>	<b>(11) International Publication Number:</b> WO 94/21308 <b>(43) International Publication Date:</b> 29 September 1994 (29.09.94)
<b>(21) International Application Number:</b> PCT/US94/02488 <b>(22) International Filing Date:</b> 9 March 1994 (09.03.94) <b>(30) Priority Data:</b> 08/033,394 18 March 1993 (18.03.93) US <b>(71) Applicant:</b> CEDARS-SINAI MEDICAL CENTER [US/US]; 8700 Beverly Boulevard, Los Angeles, CA 90048 (US). <b>(72) Inventor:</b> LAMBERT, Thomas, L., Dr.; 7100 Doe Avenue, Las Vegas, NV 89117 (US). <b>(74) Agent:</b> WHITEFORD, Wendy, A.; Pretty, Schoreder, Bruegge- mann & Clark, Suite 2000, 444 South Flower Street, Los Angeles, CA 90071 (US).		<b>(81) Designated States:</b> JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> DRUG INCORPORATING AND RELEASING POLYMERIC COATING FOR BIOPROSTHESIS  <b>(57) Abstract:</b>  In accordance with the present invention, there are provided prosthetic articles having polyurethane coatings with biologically active compounds incorporated within the interstices of the polymer. Methods for the preparation of such articles are also provided. Thus, a polyurethane coating is applied to a prosthetic article, the coating then swelled (without significantly dissolving the polymer) so that substantial quantities of biologically active compounds can be incorporated within the interstices of the polymer. Upon long term exposure of a prosthetic article of the invention to physiological conditions, the biologically active compound is slowly released by the treated polymer. The biologically active compound is, therefore, released only at the site where it is desired, i.e., where the prosthetic article is positioned.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

DRUG INCORPORATING AND RELEASING  
POLYMERIC COATING FOR BIOPROSTHESIS

FIELD OF THE INVENTION

The present invention relates to methods for localized drug delivery, as well as compositions and articles useful therefor.

5

BACKGROUND OF THE INVENTION

Currently, balloon angioplasty induced vascular injury resulting in smooth muscle proliferation contributes to a restenosis rate in excess of forty percent, leading to repeat angioplasty and bypass surgery. Despite numerous basic and clinical research efforts employing antiproliferative, antiplatelet, and antiinflammatory drugs given systemically, no effective therapy has been found in humans (McBride et al., New Eng. J. Med., 318(26):1734-1737 (1988); Liu et al., Circulation, 79(6):1374-1387 (1989)). Increasing the systemic dose of drugs to higher and potentially efficacious levels would also lead to increased toxicity in other organs. Clearly a need exists for a system that concentrates drugs locally without achieving significant systemic levels.

In one approach to prevent restenosis, researchers have attempted to deliver drugs locally in the vessel wall. However, the best means of local delivery has not been established, and very little is known of the pharmacokinetics of drugs within the vessel wall and the toxicology of large doses of drug on the integrity of the vessel. Kinetic studies of drugs delivered locally into the vessel wall to date have shown that elution of drug from the vessel wall is rapid, thus diminishing the effectiveness of the drug.

- Drug delivery from polyurethanes has previously been demonstrated. For example, Kim showed that Biomer™, a hydrophobic polymer, could release prostaglandins *in vitro* and affect platelet aggregation despite a long period of storage (McRea and Kim, Trans. Am. Soc. Artif. Intern. Organs, 24:746-752 (1978); McRea et al., Trans. Am. Soc. Artif. Intern. Organs, 27:511-516 (1981)). He noted varying rates of release of compounds from the polymer but did not investigate these differences further.
- 5      Release of heparin from intravascular catheters in quantities sufficient to decrease thrombosis on the catheter has been achieved by either covalently bonding a charged molecule to the polymer or incorporating a large nonmobile charged molecule on the surface of the polymer
- 10      (Grode et al., J. Biomed. Mater. Res. Symp., 3:77 (1972); Barbucci et al., Biomaterials, 10:299-307 (1989)). This technology has been used for antibiotics but has not been expanded to the incorporation of other drugs (Henry et al., J. Thorac. Cardio. Surg., 82:272-277 (1981)).
- 15      Recently, silicone based polymers which are capable of delivering various compounds have been implanted perivascularly, but the effect of drug was overshadowed by the inflammatory response to the polymer (Villa et al., The Restenosis Summit IV, 4:24 (1992)).
- 20      Polyvinyl alcohol based polymer beads, which are capable of delivering large quantities of heparin locally, have inhibited intimal hyperplasia when placed in the perivascular tissue in rats (Okada et al., Neurosurgery, 25:892-898 (1989)). However, clinical application for
- 25      bead placement requiring surgery is limited.
- 30      Delivery of drug from a stent coating has previously been attempted. Cox incorporated methotrexate and heparin in a cellulose ester stent coating, but failed to show a reduction in restenosis when implanted in
- 35      porcine coronary arteries (Cox et al., Circulation, 84(4): II-71 (1991)). Local delivery of drug was not quantified,

and it was not clear whether tissue levels were sufficient to block smooth muscle proliferation or whether tissue drug concentration was sufficient, but caused additional injury.

5           There is, therefore, a clear need in the art for means for the localized delivery of biologically active compounds to a subject, particularly to vascular tissue of a subject.

#### BRIEF DESCRIPTION OF THE INVENTION

10           In accordance with the present invention, it has been discovered that polyurethane coatings on prosthetic articles can be swelled (without significantly dissolving the polymer) so that substantial quantities of biologically active compounds can be incorporated within  
15 the interstices of the polymer. Swelling of the polyurethane allows drug uptake throughout the matrix which provides higher drug content than surface binding techniques.

          Upon long term exposure of a prosthetic article  
20 to physiological conditions, the biologically active compound is slowly released by the treated polymer. The biologically active compound is, therefore, released and concentrated only at the site where it is desired, i.e., where the prosthetic article is positioned. When the  
25 target tissue is in contact with the polyurethane, the biologically active compound distributes in the tissue by passive diffusion. Increasing the lipid solubility of the compound slows release from the polyurethane, and increases the tissue retention. More lipid soluble  
30 compounds are, therefore, preferred agents for use in the practice of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there is provided a method for preparing a system suitable for localized delivery of biologically active compounds to a subject. The invention method comprises subjecting a medical grade polyurethane coated substrate, and a coating expansion solution (comprising at least about 0.1 part of at least one biologically active compound per 100 parts of a suitable organic solvent system) to conditions suitable to allow penetration of the biologically active compound substantially throughout the entire thickness of the polyurethane coating. Preferably, the substrate has a polyurethane coating thickness of at least about 20 microns. The solvent treated article is then dried under conditions sufficient to substantially eliminate organic solvent from the polyurethane coating.

In accordance with another embodiment of the present invention, there is provided a drug delivery system prepared as described above. Such a drug delivery system comprises a substrate having coated thereon a thickness of at least about 20 microns of a linear, aliphatic polyurethane elastomer coating, and at least one biologically active compound absorbed into the interstices of said coating.

In accordance with yet another embodiment of the present invention, there is provided a method for the localized delivery of biologically active compounds to a subject. This invention method comprises implanting the above-described delivery system at a site where the targeted release of said biologically active compound is desired.

Biologically active compounds suitable for use in the practice of the present invention may fall anywhere on the spectrum from lipophilic to hydrophilic. However, the method for preparing a system suitable for localized

delivery of biologically active compounds will vary depending on the compatibility of the solubility characteristics of the polyurethane coating and the biologically active compounds to be incorporated therein.

5 If, for example, the polyurethane coating is lipophilic and the biologically active compound is hydrophilic, it may be necessary to link the hydrophilic drug to a lipophilic carrier in order to achieve penetration of the biologically active compound through the entire thickness  
10 of the polyurethane coating. Alternatively, the polyurethane coating may be modified to make it more amenable to penetration by the biologically active compound.

15 Biologically active compounds suitable for use in the practice of the present invention include antithrombotic agents (e.g., hirulog, D/phenylalanyl-proloyol-L-arginyl chloromethyl ketone, and IIbIIIa receptor antagonist), antiinflammatory drugs such as  
20 steroids, (e.g., triamcinolone acetonide, dexamethasone analogs), colchicine (Sigma, St. Louis, MO), retinoids (antifibrotic) (e.g., etretinate, Retin A<sup>TM</sup>), probucol (antioxidant, cholesterol lowering agent; Sigma, St. Louis, MO), tyrophostins, antiproliferative compounds  
25 (e.g., colchicine, sphingosine (a protein kinase C inhibitor, Sigma, St. Louis, MO)), angiopeptin (HBI/USA), vasodilators (e.g., molisdomine, pinacidil cGMP, CAMP, their analogs and activators), and the like. Sphingosine is of interest because of its ability to modify the  
30 polyurethane. Biologically active compounds presently preferred for use in the practice of the present invention include lipophilic compounds, for example, forskolin, sphingosine, etretinate, lipid modified oligonucleotides, and the like.


35 Potential modifications which might aid in improving retention of the biologically active compound by the subject include: (1) adding lipid sidechains to the biologically active compound to enhance lipid solubility

and retard diffusion from lipid membranes, (2) using compounds with high affinity receptors in smooth muscle cells, (3) changing the charge of the compound to alter its diffusion kinetics, and (4) binding the biologically active compound to a substance having reactivity with a specific receptor in the target tissue. Increased uptake by the polymer, decreased elution rate from the polymer, and increased tissue retention have been demonstrated using biologically active compounds having one or more 2-18 carbon sidechains. For example, etretinate which contains a long lipid side chain showed increased uptake by the polymer, decreased elution rate from the polymer and increased tissue retention as compared to forskolin which is also lipid soluble but lacks a side chain.

Substrates suitable for use in the practice of the present invention include metallic stents, such as vascular, biliary or ureteral stents, heart valves, metallic prostheses, prosthetic joints, pacemakers, catheters, balloon coatings, ocular implants, contact lenses, and the like.

Polyurethanes employed in the practice of the present invention typically have certain flexibility, strength and biocompatibility characteristics so as to enable the application of a stable coating onto substrate (i.e., the coating will be able to withstand certain handling, deformation, abrasion, exposure to various environments, and the like, to which the resulting article will be subjected). Polyurethanes which are both biocompatible and have the above-described physical properties are characterized as being linear, aliphatic polyurethane elastomers. Suitable medical grade polyurethanes can be described as the reaction product of:

a high molecular weight polyether polyol having the structure:



wherein n is such that the molecular weight



of said polyether polyol falls in the range of about 500 up to 5000, with in the range of about 1 up to 5 parts, per part polyether polyol, of an aliphatic diisocyanate, and in the range of about 1 up to 5 parts, per part polyether polyol, of a chain extender.

Aliphatic diisocyanates contemplated for use in the practice of the present invention include hexamethylene diisocyanate, isophorone diisocyanate, trimethyl hexamethylene diisocyanate, dicyclohexylmethane diisocyanate, and the like. Aromatic diisocyanates may also be used in the practice of the present invention, particularly when the substrate for the polymeric coating, for example a heart valve, favors the greater rigidity associated with aromatic linkers.

Chain extenders contemplated for use in the practice of the present invention include 1,4-butanediol and other aliphatic diols.

A presently preferred polyurethane for use in the practice of the present invention is commercially available from Thermedics, Inc. (Woburn, Massachusetts) under the tradename Tecoflex™. A family of related polymers (and details as to the preparation thereof) is described in U.S. Patent No. 4,447,590, incorporated by reference herein in its entirety.

Thickness of the polyurethane coating typically falls in the range of about 25 up to 500 microns. Degree of swelling of the polyurethane coating is dependent on the thickness of the coating, the solvent used for the swelling step and the time for which the solvent and coating are maintained in contact with one another. For example, a polyurethane coating having a thickness of about 50 microns can be expanded by up to about 10 times, without substantially dissolving the coating.

Coating expansion solutions contemplated for use in the practice of the present invention comprise a combination of a polymer solvent and a polymer non-solvent capable of expanding the polymer without dissolving it, wherein the ratio of solvent to non-solvent falls in the range of about 1:20 up to 1:1. Typically, the coating expansion solution contains in the range of about 1 up to 100 milligrams of at least one biologically active compound per milliliter of said organic solvent system.

The specific ratio of polymer solvent/non-solvent employed in the invention process is dependent upon a number of factors, e.g., the solubility characteristics of the specific polyurethane coating, the solubility characteristics of the biologically active compound, the relative toxicity of the components of the solvent system to the host in the event that the solvent cannot be completely evaporated from the system, and the like.

Organic solvents contemplated for use in the coating expansion solution employed in the practice of the present invention are selected from low molecular weight hydrocarbons (e.g., hexane, heptane, cyclohexane), low molecular weight alcohols (e.g., methanol, ethanol, isopropanol), polyethers (e.g., compounds of the structure:



wherein R is a lower alkyl group, x is a whole number from 1-4 and y is a whole number from 1-6, such as ethylene glycol dimethyl ether), cyclic ethers (e.g., tetrahydrofuran, tetrahydropyranoside, dioxane), chlorofluorocarbons (having in the range of about 1 up to 4 carbon atoms (e.g., dichloromethane), benzene or alkyl-substituted derivatives thereof, N,N-dimethyl acetamide, dimethylsulfoxide, as well as mixtures of any two or more thereof. A presently preferred solvent combination employed in the practice of the present invention comprises a mixture of ethanol and tetrahydrofuran in a

volume ratio in the range of about 2:1 up to 20:1 (i.e., in the range of about 70 to 95% ethanol and in the range of about 5 to 30% tetrahydrofuran).

Conditions suitable to allow penetration of  
5 biologically active compound throughout the stent coating  
~~typically comprise contacting the polymer-coated stent~~  
with  
coating expansion solution at room temperature for a time  
sufficient to substantially swell the coating without  
10 significantly dissolving the coating. Such time generally  
falls in the range of about 1 to 30 minutes and varies in  
accordance with the polyurethane coating and coating  
expansion solution chosen. For example, if the preferred  
polyurethane coating is contacted with a coating expansion  
15 solution containing 10% of tetrahydrofuran, then a contact  
time of about 5-10 minutes is suitable to accomplish the  
desired degree of swelling of the polyurethane coating.  
When the tetrahydrofuran content is increased to about  
25%, shorter contact times (i.e., only about 3-5 minutes)  
20 are suitable to accomplish the desired swelling of the  
polyurethane coating. When tetrahydrofuran content is  
further increased to about 40%, even shorter contact times  
(i.e., only about 1-3 minutes) are suitable to accomplish  
the desired swelling of the polyurethane coating.  
25 However, at this higher tetrahydrofuran-content, the  
structural integrity of the polyurethane coating is likely  
to be compromised if extended contact times are allowed.

The drying step contemplated for use in the  
practice of the present invention comprises subjecting the  
30 solvent-treated article to subjecting said substrate to a  
temperature in the range of about 20 up to 100°C under  
reduced pressure for a time in the range of about 4 up to  
16 hours. By "reduced pressure" it is meant pressure in  
the range of about 50-500mm Hg, or preferably about 250mm  
35 Hg. In a presently preferred embodiment, the solvent-  
treated article is initially dried by subjecting said  
article to room temperature at atmospheric pressure, for

a time in the range of about 2 up to 15 minutes to avoid irregularities in the polymer that might occur during heat drying.

5           The dried article can be rinsed in saline and should be gas sterilized prior to implantation. Appropriate procedures for implantation of articles of the present invention are well known to those of skill in the art. Of course, the appropriate procedures will vary in  
10   accordance with the nature of the article selected to act as the substrate, as well as their specific uses.

The invention will now be described in greater detail by reference to the following non-limiting examples.

15

Example 1Drug incorporation into polyurethane-coated articles

Nitinol stents or stainless steel coils with surface area similar to nitinol stents were coated with Tecoflex 85A™ polyurethane to a thickness of about 50  
20   microns in accordance with the manufacture's instructions for coating metal surfaces. Stents were then incubated in solutions containing the lipophilic dyes: rhodamine B or fluorescein dilaurate (Sigma, St. Louis, MO), or a solution of unlabeled (Calbiochem, La Jolla, CA), and  
25   tritiated forskolin (New England Nuclear, Boston, MA) with a specific activity of 10  $\mu$ Ci/mg. Forskolin, an adenylate cyclase activator with antiplatelet aggregation, antismooth muscle proliferation, and vasorelaxant properties, was selected for its lipid solubility and  
30   availability in tritiated form (Tandon et al., Blood, 67:(2):366-372 (1986); Vargas et al., Transplant Proceedings, 21(4):3702-3704 (1989); Wood et al., Br. J. Pharmacology, 96:718-724 (1989)).

The drug loading procedure is carried out as  
35   follows: The desired compound is dissolved in a solution

containing 3 parts ethanol and 1 part tetrahydrofuran (100 mg/ml for rhodamine B and 50 mg/ml for fluorescein dilaurate and forskolin). Subsequently, 20 mg/ml was used for in vivo stents containing forskolin and etretinate.

5                   When a hydrophilic compound such as hirulog was loaded in the polyurethane, the polyurethane was first loaded with sphingosine or any charged lipophilic molecule as described above. With this modification, the polyurethane will swell in organic solutions containing up to 10% water. The desired compound was then dissolved as 10 50 mg/ml in ethanol/tetrahydrofuran/water in a ratio of 65/25/1-20. The water content will vary according to the solubility of the desired compound in this solvent system.

After incubation, all stents, coils, and films 15 were dried overnight at 40°C at reduced pressure. To evaluate the ability of a charged lipid soluble drug to facilitate uptake and release of a water soluble compound, thin films containing 20 mg of polyurethane with or without 1 mg of sphingosine were produced by pour plating and drying overnight at 40°C under reduced pressure. The 20 films were then incubated in a solution of fluorescein disodium, a water soluble dye. After incubation, films were dried as described above.

#### Example 2

##### 25                   In vitro drug release

In order to assess in vitro drug release, nitinol stents or stainless steel coils (coated with polyurethane as described in Example 1) were treated as follows. After a 15 minute preincubation (wash step), 30 stents, coils, or films were incubated for 2-3 days in 2 ml. of phosphate buffered saline (pH = 7.4) or 5% bovine serum albumin in PBS at 37°C in a shaking water bath. At various times (as indicated in Table 1), media was removed and aliquots analyzed for dye or forskolin content. At 35 the end of incubations, the polyurethane was dissolved in

tertrahydrofuran and an aliquot analyzed to determine the quantity of compound remaining in the polymer. Serially diluted aliquots containing Rhodamine B, fluorescein dilaurate, and fluorescein disodium were measured for light absorption at 580, 491, and 491  $\lambda$ , respectively, and content determined by comparison to absorption curves of control solutions. Solutions containing fluorescein dilaurate required addition of 200  $\mu$ l of 10M sodium hydroxide to convert the fluorescein dilaurate into its colored form (release the two 16-carbon fatty acid dilaurate chains from the water soluble fluorescein molecule). Forskolin content was determined by scintillation counting. Results are presented in Table 1.

TABLE 1

15	Compound	Vehicle	Buffer	Release Rate ( $\mu$ g/hr)			Total (mg)
				Day 1	Day 2	Day 3	
	<u>A. Single Drug</u>						
20	Rhodamine B (n*=3)	Coil	PBS	37.0	5.2	ND*	1.5
	Forskolin (n=3)	Stents	PBS	3.8	3.9	1.6	4.4
	Fluorescein dilaurate	Coil(n=1)	5% BSA	3.4	2.3	ND	ND
25	Fluorescein dilaurate	Film(n=2)	5% BSA	4.6	3.7	ND	ND
	<u>B. Dual Drug</u>						
30	Fluorescein disodium (n=2)	Film		4.0	1.8	1.8	0.3
	Fluorescein disodium (n=2)	Film + SPH		16.0	4.0	2.0	1.1
35	*ND = not determined						
	*n = number of subjects						

As shown in Table 1A, release rates from the polyurethane vary with water solubility. Rhodamine B, the most water soluble of the group, exhibits the highest initial release rate. Forskolin, which is less soluble in aqueous solutions, concentrates to a greater extent in the hydrophobic polymer and exhibits slower release rate. Fluorescein dilaurate is insoluble in water and required

5% albumin to promote release. Table 1B reveals improved total content of fluorescein disodium, a water soluble compound, with the addition of sphingosine (SPH) to the matrix and a subsequently higher delivery rate.

5           The results of this example demonstrate that polyurethane stent coatings can concentrate and release lipophilic drugs *in vitro*. While uptake improves with increasing lipid solubility, release rates increase with water solubility. Since albumin is the major blood  
10 carrier of lipophilic molecules, *in vitro* release experiments which include albumin probably better simulate *in vivo* conditions, especially for very hydrophobic molecules such as fluorescein dilaurylate. Addition of a  
15 charged lipid-soluble molecule such as sphingosine can modify the polyurethane matrix to allow uptake of water soluble molecules.

### Example 3

#### Delivery of Forskolin to the Vascular Wall from a Polyurethane Coated Nitinol Stent

20           For these experiments, nitinol stents were coated with Tecoflex™, to a thickness of about 50-100 microns, and then incubated in a solution containing unlabelled and tritiated forskolin with a specific activity of 25  $\mu\text{Ci/mg}$ . Resulting stents contained  
25 approximately 1.5 mg. of forskolin in approximately 20 mg of 50-100 micron thick polymer matrix coating.

Thirteen 3.5 kg. New Zealand white rabbits were anesthetized with intravenous xylazine and ketamine. The left femoral and right carotid arteries were surgically  
30 exposed, a 6F sheath placed in the left femoral artery, and a 22 g. angiocath placed in a branch of the common carotid. A 2.5 mm transit time flow probe (Transonics) was placed just proximal to the carotid bifurcation. After a 1000 u intraarterial bolus of heparin, a  
35 polyurethane coated nitinol stent loaded on a 3.0 mm PTCA

balloon catheter was passed via the right femoral artery sheath and deployed in the right carotid artery by balloon expansion followed by catheter removal. Serial carotid blood flow measurements and blood samples proximal and  
5 distal to the deployed stent were collected to calculate forskolin blood levels.

To quantify acute tissue uptake, 6 rabbits received a drug-containing coated stent for 4 hours, and in 3 animals stents remained *in situ* for 24 hours before  
10 euthanasia under anesthesia was performed. To quantify tissue washout of drug, 4 stents were removed at 2 hours with the recovery catheter advanced from the femoral artery. Two animals survived for 2 hours and two for 24 hours prior to euthanasia.

15 For tissue processing, samples of adventitia were removed and the carotid artery was sectioned into 1 cm. proximal to the stent, vessel overlying the stent, and 1 cm. increments distal to the stent. Additional samples were obtained from strap muscle, fascia, and peritracheal  
20 fat adjacent to the stent, contralateral carotid artery, liver and kidney. Tissue samples were weighed ( $10 \pm 6$  mg for media,  $12 \pm 7$  for adventitia, and  $23 \pm 12$  for other tissues) immediately after collection and digested in 1 ml. of BTS-450 (Beckman, Fullerton, CA) at 40°C for 24  
25 hours and counted for one minute in 10 cc of Ready Organic scintillation fluid (Beckman, Fullerton, CA). Blood samples (0.5 ml.) were digested in 1.5 ml of 1:2 BTS-450/isopropanol at 40°C for 24 hours, decolorized with  $H_2O_2$  and counted in 18 ml. of Safety Sol™ scintillation fluid  
30 (RPI). Scintillation fluid contained 0.7% acetic acid to reduce chemiluminescence.

Instantaneous blood release rates were calculated by the following formula using the conservation of mass principle:

35 
$$dM/dT = Q (C_2 - C_1)$$
$$(mg/min = ml/min (mg/ml))$$



where  $dM$  = change in mass,  $dT$  = change in time,  $M$  = mass,  $Q$  = flow,  $C_1$  = upstream concentration, and  $C_2$  = downstream concentration. Scintillation counts were then adjusted for measured background and efficiency. The amount of forskolin present was calculated by comparison of tissue activity to a 25 uCi/mg standard. For comparison of tissue and blood forskolin concentrations, blood levels were divided by specific gravity of rabbit blood (1.050 g/ml). Statistical analysis to assess differences between the multiple sites of the tissue samples was by one-way analysis of variances (ANOVA). If significant differences were found ( $p < 0.05$ ), pairwise comparisons were then performed using the t-test within ANOVA corrected for multiple comparisons (Bonferoni/Least Significant Difference tests).

Following stent delivery, carotid artery flow increased and remained elevated in all cases [ $10.3 \pm 4.2$  ml/min vs.  $15.9 \pm 2.6$  ml/min at 1 min. ( $p < 0.005$ ) and  $19.6 \pm 4.4$  ml/min at 60 min. ( $p < 0.0001$ )]. Blood levels revealed an immediate forskolin level of 57 ng/ml followed by a gradual increase to a peak level of 140 ng/ml at three to four hours. The calculated instantaneous release rate of forskolin into the bloodstream was initially 6900 ng/min which then decreased to 700 ng/min over four hours.

The local concentration of forskolin in the removed vascular and organ tissues was determined. Media overlying the stent contained 450 times the concentration of forskolin in the blood and 385 times the concentration of forskolin in the contralateral artery. Adventitia overlying the stent contained 360 times the concentration of forskolin in the blood and 305 times the concentration of forskolin in the contralateral artery. Vessel 1 cm. proximal to the stent, media and adventitia overlying the stent, and sections one and two centimeters distal to the stent all had significant levels of forskolin when compared to contralateral artery and blood  $p < 0.001$ .

In a similar model, etretinate, a retanoic acid analog, develops concentrations in the media of 250 ng/mg tissue at 24 hours. At 24 hours, this concentration was over 2000 times the concentration in the blood.

5 Etretinate concentrations of 185 ng/mg tissue were observed after 72 hours of implantation. In addition, ten percent of the etretinate remained in the vessel wall 4 days after removal of coated stents containing etretinate when the stent had been implanted for 72 hours.

10 The radial and longitudinal diffusion of forskolin at various points proximal, distal, and radial to the stent show that there is a diffusion gradient in both longitudinal and radial directions away from the stent.

15 Twenty four hour implants (n=3) produced media levels of  $4.9 \pm 1.2$  ng/mg tissue with concomitant blood level of  $68 \pm 18$  ng/ml giving a tissue to blood ratio of  $77 \pm 22$ . Adventitia contained  $4.1 \pm 1.8$  ng FSK/mg tissue with a tissue to blood ratio of  $61 \pm 18$ .

20 In drug washout experiments, all four stents were successfully removed. Media overlying the stent contained 1.2 ng FSK/mg tissue at two hours and 0.2 ng FSK/mg at 24 hours. Adventitia contained 1.7 ng/mg at 2 hours and 0.1 ng/mg at 24 hours. Other adjacent tissues  
25 all contained  $< 0.6$  ng/mg at two hours and  $< 0.1$  ng/mg at 24 hours.

These data demonstrate that a polyurethane coated nitinol stent is capable of delivering a lipophilic drug in high local concentration in the vessel wall. The  
30 large 600 fold differential of local tissue levels of forskolin over blood levels reflects the capability of this delivery system to provide high local concentration and potentially higher efficacy, with lower risk of systemic side effects. Diffusion of drug appears to  
35 follow a concentration gradient from stent to media then

both radially and longitudinally into adjacent tissue. Release rates *in vivo* were also 10 fold greater than the *in vitro* release rate (7.0 ug/min vs. 0.5 ug/min) probably due to increased solubility of forskolin in blood and the constant current of blood and volume of distribution not reproduced by the shaker bath. Washout of forskolin from the vessel wall was rapid, suggesting that the measured tissue levels reflect a balance of drug uptake and release from the tissue.

10

Example 4Inhibition of Thrombosis by Forskolin Eluting  
for a Polyurethane Coated Nitinol Stent

To evaluate the thrombogenicity of polyurethane stent coatings, a rabbit carotid crush injury, low flow thrombosis model was developed. Briefly, New Zealand white rabbits (n = 14) underwent anesthesia with ketamine and xylazine followed by surgical exposure of the right carotid and left femoral arteries. A 6 french sheath was placed in the left femoral artery and a 2.0 mm transit time flow probe (Transonics) was placed in the distal carotid artery. No anticoagulant was given. Repeated crush injury with a plastic coated clamp was performed at similar force for fifteen times over a one cm. distance usually producing a small decrement in flow rate. After 5 minutes, a bare or polyurethane coated nitinol stent was advanced to straddle the area of injury and balloon expanded. After a 15 minute equilibration period during which a 3.0 mm balloon occluder was placed proximal to the stent, the occluder was inflated to reduce flow to 4 ml/min. (40% of baseline). Continuous pressure monitoring via pressure transducer placed on line in the occluder inflation system was performed to ensure maintenance of consistent occlusion.

Continuous carotid artery flow and mean blood pressure were recorded by strip chart recorder. If the flow remained < 0.5 ml/min, for 5 minutes, the artery was

considered occluded and experiment terminated. If the artery exhibited flow  $< 0.5$  ml/min but returned to flows above 0.5 ml/min intermittent occlusion or cyclic flow variation was determined to be present. After euthanasia, the artery was removed and cut longitudinally with a scalpel. The polyurethane coating was visually inspected for defects. Presence of white or red thrombus was also noted. The time to cyclic flow (TCF) and time to occlusion (TTO) for the above-described stents are summarized in Table 2.

Table 2  
Time to Cyclic Flow (TCF) and Time to Occlusion (TTO)  
for Forskolin Treated and Control Stents

	TCF (min)	TTO (min)
Uncoated (n=5)	16 $\pm$ 13	19 $\pm$ 18
15 Polymer Coated (n=4)	27 $\pm$ 17	54 $\pm$ 27 (a)
Forskolin Treated (n=5)	208 $\pm$ 71 (b)	>240
	(a) $p < 0.02$ compared to uncoated.	
20	(b) $p < 0.0001$ compared to coated and uncoated.	

Two of the uncoated stents, all of the coated stents, and one of the forskolin impregnated stents exhibited cyclic carotid blood flow. As seen in Table 2, impregnation of forskolin into the polyurethane remarkably increased the time to cyclic flow (TCF) and time to occlusion (TTO). In comparison, coating with polyurethane alone only had a modest impact on time to occlusion and no significant increase in time to cyclic flow. Upon visual inspection, uncoated stents appeared to have mixed red and white thrombus, coated stents had predominately white thrombus, and one forskolin impregnated stent had red thrombus only.

These results suggest that forskolin released from the polyurethane is biologically active and prevented

thrombosis of the stented segment compared to uncoated and coated stents. Absence of platelet rich white thrombus in the forskolin treated stent segments suggests that inhibition of platelet aggregation decreased thrombus  
5 formation.

While the invention has been described in detail with reference to certain preferred embodiments thereof, it will be understood that modifications and variations are within the spirit and scope of that which is described  
10 and claimed.

## Claims:

1. A method for preparing a system suitable for localized delivery of biologically active compounds to a subject, said method comprising subjecting a combination comprising:

- 5 an article comprising a substrate having a medical grade polyurethane coating at least 20 microns thick thereon, and a coating expansion solution containing at least 0.1 parts, per 100 parts of an organic solvent system, of at least one  
10 biologically active compound to conditions suitable to allow penetration of the biologically active compound substantially throughout the entire thickness of said polyurethane coating; and  
15 thereafter drying the solvent treated article under conditions sufficient to substantially eliminate organic solvent from said polyurethane coating.

2. A method according to claim 1 wherein said conditions suitable to allow penetration of the biologically active compound comprises contacting said article with said coating expansion solution at room  
5 temperature for a time sufficient to substantially swell the coating without significantly dissolving the coating.

3. A method according to claim 2 wherein said article is contacted with said coating expansion solution for a time in the range of about 1 up to 30 minutes.

4. A method according to claim 2 wherein the coating expansion solution comprises a combination of a polymer solvent and a polymer non-solvent capable of expanding the polymer without dissolving it, wherein the  
5 ratio of solvent to non-solvent falls in the range of about 1:20 up to 1:1.

5. A method according to claim 2 wherein the coating expansion solution contains in the range of about 1 up to 100 milligrams of at least one biologically active compound per milliliter of said organic solvent system.

6. A method according to claim 1, wherein the organic solvent employed in the coating expansion solution is selected from low molecular weight hydrocarbons, low molecular weight alcohols, polyethers, cyclic ethers, 5 chlorofluorocarbons, benzene or alkyl-substituted derivatives thereof, N,N-dimethyl acetamide, as well as mixtures of any two or more thereof.

7. A method according to claim 1, wherein the organic solvent in the coating expansion solution comprises a mixture of ethanol and tetrahydrofuran in a volume ratio in the range of about 2:1 up to 20:1.

8. A method according to claim 1, wherein the substrate is selected from a metallic stent, a heart valve, a metallic prosthesis, a prosthetic joint, a pacemaker, a catheter, a balloon coating, an ocular 5 implant or a contact lens.

9. A method according to claim 1, wherein the thickness of said polyurethane coating falls in the range of about 20 up to 500 microns.

10. A method according to claim 1, wherein the medical grade polyurethane is a linear, aliphatic polyurethane elastomer.

11. A method according to claim 10 wherein said medical grade polyurethane is the reaction product of:

a high molecular weight polyether polyol having the structure:



wherein n is such that the molecular weight of said polyether polyol falls in the range of about 500 up to 5000, with

10                    in the range of about 1 up to 5 parts, per part polyether polyol, of an aliphatic diisocyanate, and

in the range of about 1 up to 5 parts, per part polyether polyol, of a chain extender.

12. A method according to claim 11 wherein said aliphatic diisocyanate is selected from hexamethylene diisocyanate, isophorone diisocyanate, trimethyl hexamethylene diisocyanate, or dicyclohexylmethane  
5 diisocyanate.

13. A method according to claim 11 wherein said chain extender is 1,4-butanediol.

14. A method according to claim 1, wherein the biologically active compound is a lipophilic compound.

15. A method according to claim 14 wherein said biologically active compound is selected from forskolin, sphingosine, atretinate or a lipid modified oligonucleotide.

16. A method according to claim 14 wherein said drug is a hydrophilic drug, said method further comprising linking the hydrophilic drug to a lipophilic carrier.



17. A method according to claim 1, wherein said drying step comprises subjecting the solvent-treated article to a temperature in the range of about 20°C up to about 100°C under reduced pressure for a time in the range of about 4 up to 16 hours.


18. A method according to claim 17 wherein the solvent-treated article is initially dried by subjecting said article to room temperature at atmospheric pressure, for a time in the range of about 2 up to 15 minutes.

19. A method of preparing a system suitable for the localized delivery of biologically active compounds to a subject, said method comprising:

contacting an article comprising a metallic stent having a substantially uniform coating thereon of medical grade polyurethane having a thickness of at least about 20 microns, with a coating expansion solution containing at least 50 mg of at least one drug per ml of an organic solvent system, wherein said organic solvent system comprises a mixture of ethanol and tetrahydrofuran in a volume ratio in the range of about 2:1 up to 20:1; wherein said contacting is carried out at room temperature for a time in the range of 1 up to 30 minutes;

wherein said medical grade polyurethane is the reaction product of:

a high molecular weight polyether polyol having the structure:



wherein n is such that the molecular weight of said polyether polyol falls in the range of about 500 up to 5000, with

in the range of about 1 up to 5 parts, per part polyether polyol, of an aliphatic diisocyanate, wherein said aliphatic diisocyanate is selected from hexamethylene diisocyanate, isophorone diisocyanate, trimethyl hexamethylene diisocyanate, or dicyclohexylmethane diisocyanate; and

30 in the range of about 1 up to 5 parts, per part  
polyether polyol, of 1,4-butanediol, as a  
chain extender, and

35 drying the solvent-treated article by first  
subjecting said article to room temperature and  
atmospheric pressure, for a time in the range of about 2  
up to 15 minutes, and thereafter subjecting the solvent-  
treated article to a temperature in the range of about 20  
up to 100°C at a pressure in the range of about 100 up to  
500 mm Hg for a time in the range of about 4 up to 16  
hours.


20. A system suitable for localized delivery of  
biologically active compounds to a subject, said system  
prepared by the method of claim 1.

21. A drug delivery system comprising a  
substrate having coated thereon a thickness of at least 20  
microns of a medical grade polyurethane coating, and at  
least one biologically active compound absorbed into the  
5 interstices of said coating.

22. A drug delivery system according to claim  
21, wherein said medical grade polyurethane is a linear,  
aliphatic polyurethane elastomer.

23. A drug delivery system according to claim  
22 wherein said linear, aliphatic polyurethane elastomer  
coating is the reaction product of:

a high molecular weight polyether polyol having  
5 the structure:



wherein n is such that the molecular weight  
of said polyether polyol falls in the range  
of about 500 up to 5000, with  
10 in the range of about 1 up to 5 parts, per part  
polyether polyol, of an aliphatic  
diisocyanate, and

in the range of about 1 up to 5 parts, per part polyether polyol, of a chain extender.

24. A drug delivery system according to claim 23 wherein said aliphatic diisocyanate is selected from hexamethylene diisocyanate, isophorone diisocyanate, trimethyl hexamethylene diisocyanate, or  
5 dicyclohexylmethane diisocyanate.

25. A drug delivery system according to claim 23 wherein said chain extender is 1,4-butanediol.

26. A drug delivery system according to claim 21 wherein said biologically active compound is a lipophilic compound.

27. A method for the localized delivery of biologically active compounds to a subject, said method comprising implanting the delivery system of claim 21 at a site where the targeted release of said biologically  
5 active compound is desired.

# INTERNATIONAL SEARCH REPORT

Internat. Application No

PCT/US 94/02488

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 5 A61L27/00 A61L29/00 A61L31/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 5 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,92 15286 (NOVA PHARMACEUTICAL CORP.) 17 September 1992	1-10
A	EP,A,0 520 160 (BOC HEALTH CARE, INC.) 30 December 1992	1-27
A	EP,A,0 405 284 (HERCULES INCORPORATED.) 2 January 1991 see examples	1-27
A	WO,A,92 11877 (UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORP.) 23 July 1992 see the whole document	1
A	WO,A,89 04682 (COLORADO BIOMEDICAL INCORPORATED) 1 June 1989 see claims	1
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

7 July 1994

Date of mailing of the international search report

26. 07. 94

Name and mailing address of the ISA

European Patent Office, P.O. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

ESPINOSA, M

# INTERNATIONAL SEARCH REPORT

Application No  
PCT/US 94/02488

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>EP,A,0 207 624 (THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK.) 7 January 1987 see examples</p> <p>-----</p>	1

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 94/02488

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 27  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim 27 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Application No

PCT/US 94/02488

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9215286	17-09-92	AU-A- 1579092	06-10-92
EP-A-0520160	30-12-92	CA-A- 2068168	29-12-92
EP-A-0405284	02-01-91	CA-A- 2017332	29-12-90
WO-A-9211877	23-07-92	US-A- 5295978	22-03-94
		AU-B- 638883	08-07-93
		AU-A- 9161491	17-08-92
		EP-A- 0517890	16-12-92
		JP-T- 5505125	05-08-93
WO-A-8904682	01-06-89	US-A- 4917686	17-04-90
		AU-B- 635197	18-03-93
		AU-A- 2725888	14-06-89
		EP-A- 0393100	24-10-90
EP-A-0207624	07-01-87	US-A- 4612337	16-09-86
		AU-B- 586863	27-07-89
		AU-A- 5808686	04-12-86
		CA-A- 1268118	24-04-90
		JP-C- 1629398	20-12-91
		JP-B- 2056103	29-11-90
		JP-A- 62011457	20-01-87